News

<a href="https://www.ghp-news.com/winners/genetica-us/" rel="noopener noreferrer" target="_blank">Global Health &amp; Pharma's Biotechnology Awards</a>&nbsp;recognize pioneers and innovators in the crucial field of biotechnology. The award is based on nominees' achievements, business performance, growth, breakthrough innovations, and customer feedback. To make the final selection, the Global Health &amp; Pharma Voting Panel collects independent information from various publicly available sources.<img src="https://api.genetica.asia/storage/TMmHVeiaOI2hadxBtg0QhvjqCneg4cBhyHdvXQkB.webp">GENETICA US, a US biotech company, has played a leading role in the genetic testing industry by utilizing propriety technologies in AI and molecular biotechnology. The company's scientists come from some of the world's most prestigious universities, including the University of California San Francisco, Harvard, Stanford, and Cornell. With headquarters in San Francisco, GENETICA US has established itself in the Southeast Asian market by cultivating precision medicine and personalized preventative care.GENETICA US provides low-cost genetic testing solutions to the wider population, decoding hundreds of genes and almost a million variants to provide bespoke reports for optimal plans for fitness and diet, child development, and critical illness prevention. The company's core technology is built across three key pillars – gene decoding chips, AI, and blockchain – recognized by leading organizations such as <a href="https://www.thermofisher.com/vn/en/home.html" rel="noopener noreferrer" target="_blank">Thermo Fisher</a>, a world-leading gene testing provider.Despite its innovative nature, the company has encountered one major challenge.<h2> </h2><h2>Lack of Understanding in Genetic Testing</h2>Although genetic testing is becoming more widely known, many people do not understand how it works. This can result in harm and therefore it is important for GENETICA US to educate people about the industry. One reason for the lack of understanding is that each laboratory has different standards, which can affect the accuracy of results. Therefore, customers who have had domestic test reports may be asked to re-test when sent to the US or other countries to meet international standards.GENETICA US meets these standards, complying with international regulations such as CLIA and HIPPA. In October 2021, GENETICA US collaborated with the Vietnam National Innovation Centre to develop the largest genome sequencing center in Southeast Asia, which will meet international standards and ensure accurate test results, diagnostics, and high personal security levels.During the Covid-19 pandemic, GENETICA US developed a tool called G-Immunity, which aims to provide information about the risk of viral infections through each patient's genetic parameters. The company's research team used artificial intelligence and machine learning to find an effective method to combat the virus.The new genome sequencing center will meet the increasing demand for genetic testing across Vietnam, saving time and reducing costs by up to 30% compared to sending samples for analysis in a laboratory in the US. The laboratory will also collaborate with leading hospitals such as Harvard Medical University, Hue Central Hospital, and Vietnam National Hospital for Tropical Diseases to cultivate new discoveries about genetic diseases and contribute to the development of gene therapy treatments.

Genetica, a San Francisco-based genetic testing biotech company, was awarded "Best AI-Powered Genetic Testing Biotech Company"  in the Biotechnology Award category by Global Health & Pharma magazine (UK) in 2022

Genetica is awarded The Best AI-Powered Genetic Testing Biotech Company

Genetica and GenomicDAO’s core technology, upon which it conducts its testing, is built across three key pillars – gene decoding chips, artificial intelligence, and blockchain.<h2> </h2><h2>The growth of Precision Medicine sector</h2>Precision Medicine is an innovative approach to disease prevention and treatment that considers people's genetic, environmental &amp; lifestyle, of which global market size was valued at USD 66.1 billion in 2021 and is expected to reach USD 175.64 billion by 2030 (source: <a href="https://www.precedenceresearch.com/precision-medicine-market" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Precedence Research</a>).&nbsp;The sector is poised to grow at a compound annual growth rate (CAGR) of 11.5% during the forecast period 2022 to 2030, due to the advancement in cancer biology, increased adoption of gene therapy globally, rising use of big data analytics in precision medicine in developed countries, and patient involvement in personal healthcare.Established in 2015, at the heart of Precision Medicine’s fastest-growing market Asia Pacific, Genetica has steadily captured the movement with over 100,000 genetic profiles through its proprietary gene decoding services using artificial intelligence.&nbsp;<h2> </h2><h2>GenomicDAO | A Decentralized Autonomous Organization&nbsp;</h2>GenomicDAO breaks free from the centralization of modern medicine R&amp;D by establishing a community that initiates, drives, and governs precision medicine initiatives.&nbsp;Members are incentivized for contributing funds and genetic data to GenomicDAO precision medicine initiatives and reap the financial and medical benefits and successes.&nbsp;<h2> </h2><h2>Marketplace | One-stop Shop for Genetic Products</h2>GenomicDAO's ultimate goal is to develop working products addressing the health causes initiated by its community. Created and owned by GenomicDAO, these genetic products across the GenomicDAO evolution include genetic insights, personalized recommendations, and precision medicine drugs.Eventually, the GenomicDAO platform will serve as the launchpad to bootstrap various precision medicine initiatives, followed by a dedicated subsidiary DAO.To accomplish such progressive goals, GenomicDAO is built on a strong foundation consisting of proprietary technology in partnership with top gene decoding companies, led by biotech veterans, and a world-class advisory board in both the traditional and blockchain space.&nbsp;Genetica Achievement Highlights:&nbsp;<ul><li>$2.5M Raised in Seed Round within 30 days</li><li>Partnership with Illumina® &amp; Thermo Fisher, two of the world's leading genomics organizations</li><li>Expansive 20+ products in the portfolio from comprehensive healthcare to nutrition, sports, and early disease prevention (stroke, allergy, diabetes, cancer,...)</li><li>Proven accuracy of 99.9% by the US technology standards</li><li>Awarded The Best AI-Powered Genetic Testing Biotech Company by <a href="https://www.ghp-news.com/" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">Global Health &amp; Pharma</a>&nbsp;</li><li>Advised by top scientists from world-renowned universities such as UCSF, Harvard, Stanford, Cornell</li></ul>GenomicDAO has kicked off its first initiative - GenomicDAO G-Stroke with the official token listing set on February 20, 2023.&nbsp;<h2 class="ql-align-justify"> </h2><h2 class="ql-align-justify">PCSP: Governance &amp; Utility token of GenomicDAO G-Stroke</h2>Full tokenomics: <a href="https://docs.genomicdao.com/genomicdao-whitepaper/token-economy" rel="noopener noreferrer" target="_blank" style="color: rgb(17, 85, 204);">https://docs.genomicdao.com/genomicdao-whitepaper/token-economy</a>&nbsp;Details about token PCSP:<ul><li class="ql-align-justify">Token Symbol: PCSP</li><li class="ql-align-justify">Network: BEP-20</li><li class="ql-align-justify">Total Supply: 1,000,000,000</li><li class="ql-align-justify">Public Sale: N/A</li></ul>Token allocation:&nbsp;<ul><li class="ql-align-justify">Community Development: 100,000,000</li><li class="ql-align-justify">Developer Endowment: 100,000,000</li><li class="ql-align-justify">Strategic Partners: 50,000,000</li><li class="ql-align-justify">Liquidity: 50,000,000</li><li class="ql-align-justify">Team: 100,000,000</li><li class="ql-align-justify">Advisor: 50,000,000</li><li class="ql-align-justify">R&amp;D: 150,000,000</li><li class="ql-align-justify">Reserved for GenomicDAO's next stage evolution: 100,000,000</li><li class="ql-align-justify">GenomicDAO Launchpad: 300,000,000</li></ul>

Leading AI biotech company Genetica has launched the decentralized science platform GenomicDAO to empower billions of people to join forces for the advancement of Precision Medicine